Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

2,189

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

2,189 results for “AML”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov36/100

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

ClinicalTrials.gov study NCT03614728. IPD Sharing: YES. Countries: 2. Publications: 1.

controlledIPD-YESFeb 2026View details →
dryad36/100

RNA sequencing of AML cells treated with milademetan, selinexor and the combination of milademetan and selinexor

Open the record for dataset details and reuse information.

publicNov 2023View details →
zenodo32/100

Proteomics and phosphoproteomics analysis of the tyrosine phosphatase SHP2 acquired resistance to SHP099 in the context of AML

<p>Proteomics analysis of AML cell lines (MV-4-11, MOLM-13, EOL-1 and OCI-M1) presenting acquired resistance to SHP099 and their parent sensitive cells in presence of the SHP2 allosteric inhibitor SHP099 or DMSO (control). These samples were labelled with TMT and analysed by mass spectrometry.&nbsp;</p> <p>The same approach was conducted to analyse the phosphoproteome of MV-4-11 cells (parent and resistant) upon SHP099 treatment.</p> <p>These data are associated with the manuscript &quot;<strong>Tyr-62 phosphorylation of the tyrosine phosphatase SHP2 enables acquired resistance to SHP2 allosteric inhibitors</strong>&quot;</p>

openbsd-2-clause-netbsdJan 2021View details →
zenodo32/100

Proteomic and phosphoproteomic profiling of AML

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2024View details →
zenodo32/100

Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML

<p>Images utilized in the paper&nbsp;<em>Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML </em>- by&nbsp; Gui, Bingham et al.<em><br></em></p>

opencc-by-4.0Jul 2024View details →
zenodo32/100

DICOM converted Slide Microscopy images for the CPTAC-AML collection

<p>This dataset corresponds to a collection of images and/or image-derived data available from National Cancer Institute <a href="https://portal.imaging.datacommons.cancer.gov/">Imaging Data Commons (IDC)</a> [1]. This dataset was converted into DICOM representation and ingested by the IDC team. You can explore and visualize the corresponding images using IDC Portal here: <a href="https://portal.imaging.datacommons.cancer.gov/explore/filters/?collection_id=cptac_aml">CPTAC-AML</a>. You can use the manifests included in this Zenodo record to download the content of the collection following the <b>Download instructions</b> below.</p> <h3>Collection description</h3> <p> <span>This collection contains subjects from the National Cancer Institute&rsquo;s <u><a href="https://proteomics.cancer.gov/programs/cptac" rel="nofollow">Clinical Proteomic Tumor Analysis Consortium</a></u> Acute Myeloid Leukemia (CPTAC-AML) cohort.&nbsp;<span>CPTAC is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.</span></span></p> <p> Please see the <a href="">CPTAC-AML <i></i></a> wiki page to learn more about the images and to obtain any supporting metadata for this collection.</p> <h3>Files included</h3> <p>A manifest file's name indicates the IDC data release in which a version of collection data was first introduced. For example, <code>collection_id-idc_v8-aws.s5cmd</code> corresponds to the contents of the <code>collection_id</code> collection introduced in IDC data release v8. If there is a subsequent version of this Zenodo page, it will indicate when a subsequent version of the corresponding collection was introduced.</p> <ol> <li><code>cptac_aml-idc_v10-aws.s5cmd</code>: manifest of files available for download from public IDC Amazon Web Services buckets</li> <li><code>cptac_aml-idc_v10-gcs.s5cmd</code>: manifest of files available for download from public IDC Google Cloud Storage buckets</li> <li><code>cptac_aml-idc_v10-dcf.dcf</code>: Gen3 manifest (for details see <a href="Gen3 manifest documentation">https://learn.canceridc.dev/data/organization-of-data/guids-and-uuids</a>)</li> </ol> <p>Note that manifest files that end in <code>-aws.s5cmd</code> reference files stored in Amazon Web Services (AWS) buckets, while <code>-gcs.s5cmd</code> reference files in Google Cloud Storage. The actual files are identical and are mirrored between AWS and GCP.</p> <h3>Download instructions</h3> <p>Each of the manifests include instructions in the header on how to download the included files.</p> <p>To download the files using <code>.s5cmd</code> manifests:</p> <ol> <li>install <a href="https://github.com/ImagingDataCommons/idc-index">idc-index</a> package: <code>pip install --upgrade idc-index</code></li> <li>download the files referenced by manifests included in this dataset by passing the <code>.s5cmd</code> manifest file: <code>idc download manifest.s5cmd</code>.</li> </ol> <p>To download the files using <code>.dcf</code> manifest, see manifest header.</p> <h3>Acknowledgments</h3> <p>Imaging Data Commons team has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Task Order No. HHSN26110071 under Contract No. HHSN261201500003l.</p> <h3>References</h3> <p>[1] Fedorov, A., Longabaugh, W. J. R., Pot, D., Clunie, D. A., Pieper, S. D., Gibbs, D. L., Bridge, C., Herrmann, M. D., Homeyer, A., Lewis, R., Aerts, H. J. W., Krishnaswamy, D., Thiriveedhi, V. K., Ciausu, C., Schacherer, D. P., Bontempi, D., Pihl, T., Wagner, U., Farahani, K., Kim, E. &amp; Kikinis, R. <i>National Cancer Institute Imaging Data Commons: Toward Transparency, Reproducibility, and Scalability in Imaging Artificial Intelligence</i>. RadioGraphics (2023). <a href="https://doi.org/10.1148/rg.230180">https://doi.org/10.1148/rg.230180</a></p>

opencc-by-3.0Aug 2024View details →
ClinicalTrials.gov32/100

BL-8040 Addition to Consolidation Therapy in AML Patients

ClinicalTrials.gov study NCT02502968. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

ClinicalTrials.gov study NCT03661515. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS

ClinicalTrials.gov study NCT01617226. IPD Sharing: Not stated. Countries: 1. Publications: 11.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

ClinicalTrials.gov study NCT00684918. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

ClinicalTrials.gov study NCT02942758. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

ClinicalTrials.gov study NCT02928523. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

ClinicalTrials.gov study NCT04849910. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

ClinicalTrials.gov study NCT01167166. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

ClinicalTrials.gov study NCT04062266. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

ClinicalTrials.gov study NCT04541277. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

ClinicalTrials.gov study NCT01352650. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

ClinicalTrials.gov study NCT06451861. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

ClinicalTrials.gov study NCT02319369. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

ClinicalTrials.gov study NCT05994690. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record